KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Operating Income (2016 - 2025)

Historic Operating Income for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $217.9 million.

  • Halozyme Therapeutics' Operating Income rose 3353.25% to $217.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $737.4 million, marking a year-over-year increase of 5458.79%. This contributed to the annual value of $551.5 million for FY2024, which is 6336.42% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Operating Income stood at $217.9 million, which was up 3353.25% from $202.4 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Operating Income ranged from a high of $217.9 million in Q3 2025 and a low of $34.1 million during Q2 2022
  • Moreover, its 5-year median value for Operating Income was $93.0 million (2021), whereas its average is $105.0 million.
  • Its Operating Income has fluctuated over the past 5 years, first surged by 167415.45% in 2021, then tumbled by 6339.48% in 2022.
  • Halozyme Therapeutics' Operating Income (Quarter) stood at $56.5 million in 2021, then skyrocketed by 31.8% to $74.5 million in 2022, then skyrocketed by 35.6% to $101.0 million in 2023, then soared by 73.7% to $175.5 million in 2024, then increased by 24.17% to $217.9 million in 2025.
  • Its Operating Income stands at $217.9 million for Q3 2025, versus $202.4 million for Q2 2025 and $141.5 million for Q1 2025.